MELBOURNE, AUSTRALIA / ACCESSWIRE / June 22, 2015 / Propanc Health Group Corporation (OTCPK: PPCH) (“Propanc” or “the Company”), an emerging healthcare company focusing on the development of new and proprietary treatments for cancer patients, today announced that Dr Joseph Chalil has joined Propanc’s Scientific Advisory Board as an independent expert to advise on the Company’s drug development programs, in particular, Propanc’s lead product, PRP.
Dr. Chalil (42) is a Physician and Executive at Boehringer Ingelheim, the world’s largest privately held pharmaceutical company. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.
Dr. Chalil is an expert in US Healthcare policy and a strong advocate for patient centered care, and has also served as an advisor to various national political campaigns on healthcare issues. Dr. Chalil completed his higher studies in University of Medicine and Dentistry of New Jersey, Davenport University, JJM Medical College and Baylor College of Medicine. He has been a Visiting Professor at various Universities and serves on various company Boards.
“I am delighted to announce Dr Chalil’s appointment to our Scientific Advisory Board,” said James Nathanielsz, Propanc’s Chief Executive Officer. “Dr Chalil is a highly respected key opinion leader in the pharmaceutical sector. He is passionate about drug development, finding new ways to improve health, globally. There is no doubt he will add tremendous value and insight into our current and future drug development programs.”
“Propanc is an example of emerging biotech companies with new technologies which potentially could help improve the standard of healthcare, long term,” said Dr Chalil. “Where possible I look forward to assisting the management team progress their product candidates through the various milestones. Their lead product PRP appears to have a novel mechanism of action which is interesting and could have potential benefits, clinically.”
In addition to his responsibilities at Boehringer Ingelheim, Dr. Chalil is the Chairman of Global Clinical Research and Trial Network of the American Association of Physicians of Indian Origin (AAPI) and has served as Scientific Advisor to AAPI for the past five years. AAPI is the second largest physician organization in the US second only to AMA, and the largest ethnic medical organization in the country.
A veteran of the United States Navy Medical Corps, Dr. Chalil is also board certified in healthcare management, and has been awarded Fellowship by the American College of Healthcare Executives, an international professional society of more than 40,000 healthcare executives who lead hospitals, healthcare systems and other healthcare organizations.
About Propanc:
We are a development stage healthcare company that is currently focused on developing new cancer treatments for patients suffering from pancreatic and colorectal cancer. Together with our scientific and oncology consultants, we have developed a rational, composite formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our leading products are variations upon our novel formulation and involve or employ proenzymes, which are inactive precursors of enzymes. As a result of positive early indications of the anti-cancer effects of our technology, we intend to submit our proenzyme treatment to the rigorous, formal non-clinical and clinical development and trial processes required to obtain the regulatory approval necessary to commercialize it and any product(s) derived and/or to be derived therefrom.
In the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors such as colorectal or pancreatic tumors. In the future, we intend to development our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, please visit: www.propanc.com.
Forward-looking Statements:
Certain of the matters discussed in this announcement involve risks and uncertainties including, without limitation, those regarding the Company’s ability to establish and maintain the proprietary nature of its technology through the patent process, its ability to license from others patents and patent applications, if necessary, to develop certain products, its ability to implement its long range business plan for various applications of its technology, and its ability to enter into agreements with any necessary marketing and/or distribution partners for purposes of commercialization. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the company’s financial position. See Propanc’s most recent Quarterly Report on Form 10-Q and related 8K filings.
Contact:
Regal Consulting
Tel: 702 – 575 – 9157
SOURCE: Propanc Health Group Corporation
ReleaseID: 430019
